A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The proportion of patients achieving LDL-C target as defined by Swiss cholesterol
recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80
mg of atorvastatin.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.